Curis (CRIS) Stock Price, News & Analysis

Company Overview

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Key Stats

• Today's Range: $1.98 to $2.15
• 50-Day Range: $1.16 to $2.95
• 52-Week Range: $1.02 to $12.66
• Volume: 67,701 shs
• Average Volume: 70,341 shs
• Market Capitalization: $21.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.00
• Consensus Rating: Buy

Curis Stock Analysis - MarketRank™

Curis scored higher than 55% of companies evaluated by MarketBeat, and ranked 977th out of 1,850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Curis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Curis has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Curis are expected to grow in the coming year, from ($7.12) to ($3.49) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Curis is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Curis is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Curis has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.48% of the float of Curis has been sold short.

Short Interest Ratio / Days to Cover

Curis has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Curis has recently decreased by 35.70%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Curis does not currently pay a dividend.

Dividend Growth

Curis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.48% of the float of Curis has been sold short.

Short Interest Ratio / Days to Cover

Curis has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Curis has recently decreased by 35.70%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.19

News Sentiment

Curis has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Curis this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for CRIS on MarketBeat in the last 30 days.

MarketBeat Follows

Only 3 people have added Curis to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Curis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.45% of the stock of Curis is held by insiders.

Percentage Held by Institutions

Only 29.97% of the stock of Curis is held by institutions.

CRIS Stock Analysis - Frequently Asked Questions

How have CRIS shares performed this year?

Curis' stock was trading at $3.06 on January 1st, 2025. Since then, CRIS stock has decreased by 33.7% and is now trading at $2.03.
View the best growth stocks for 2025 here.

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) issued its quarterly earnings data on Tuesday, May, 6th. The biotechnology company reported ($1.25) EPS for the quarter, missing analysts' consensus estimates of ($1.14) by $0.11. The biotechnology company earned $2.38 million during the quarter, compared to analyst estimates of $2.37 million. Curis had a negative trailing twelve-month return on equity of 923.37% and a negative net margin of 443.35%.
Read the conference call transcript.

When did Curis' stock split?

Shares of Curis reverse split before market open on Friday, September 29th 2023. The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Curis' major shareholders?

Curis' top institutional investors include Armistice Capital LLC (9.88%), Wealthquest Corp (8.65%), Wealthquest Corp (8.65%) and CM Management LLC (2.83%).
View institutional ownership trends.

How do I buy shares of Curis?

Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Curis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Curis investors own include Micron Technology (MU), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), NIO (NIO), Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 5/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CRIS
• CIK: 1108205
• Web: www.curis.com
• Phone: (617) 503-6500
• Fax: 617-503-6501
• Employees: 60
• Year Founded: 2000

Price Target and Rating

• Average Stock Price Target: $16.00
• High Stock Price Target: $16.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +676.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($6.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-47,410,000.00
• Net Margins: -443.35%
• Pretax Margin: -443.35%
• Return on Equity: -923.37%
• Return on Assets: -78.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.22
• Quick Ratio: 1.22

Sales & Book Value

• Annual Sales: $11.20 million
• Price / Sales: 1.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.34 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 10,462,000
• Free Float: 7,984,000
• Market Cap: $21.55 million
• Optionable: No Data
• Beta: 3.65